Your session is about to expire
← Back to Search
CAR T Cell Therapy for Ovarian and Peritoneal Cancer
Study Summary
This trial is testing a new type of cancer treatment involving genetically modified immune cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am HIV positive.I am not receiving any treatment for brain or spinal cord disease.I do not have any active or uncontrolled infections.I am scheduled to receive high dose corticosteroids.I am taking strong medication for an autoimmune disease.My organs and bone marrow are functioning well.I am fully active or can carry out light work.My cancer is a high-grade serous type and does not respond to platinum-based treatments.I have an active cancer that is not ovarian cancer.I do not have symptoms from cancer spread to my brain.I have hepatitis B or C.I have had fluid drained from my abdomen within the last 4 weeks.My cancer is a high-grade serous type in the ovary, fallopian tube, or peritoneum and can be treated with platinum-based therapy or not.I have tried at least two chemotherapy treatments for my advanced disease without success.I have brain metastases that have been treated, and I am not on steroids.I do not have cancer spread to the lining of my brain or spinal cord.I have previously received treatment with lentiviral gene modified cells.My tumor shows high levels of aFR.I need extra oxygen.I am 18 years old or older.
- Group 1: Cohort 1: MOv19-BBz CAR T cells without chemo
- Group 2: Cohort 2: MOv19-BBz CAR T cells after chemo
- Group 3: Cohort 3: MOv19-BBz CAR T cells after chemo
- Group 4: Cohort-1: without chemo;only if dose de-escalation required
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are participants currently being enrolled in this research?
"As per the details provided on clinicaltrials.gov, this research is currently enrolling individuals into its study group. The trial was initially posted in October 2018 and has recently been updated as of September 2022."
Has the FDA granted approval to MOv19-BBz CAR T cells?
"MOv19-BBz CAR T cells have limited clinical data to support their safety and efficacy, so they were assigned a score of 1."
What is the sample size of participants enrolled in this experiment?
"Affirmative. According to the data hosted on clinicaltrials.gov, this medical trial is actively recruiting patients that were first mentioned in October 2018 and recently updated in September 2022. The study requires 18 individuals from 1 centre for participation."
Share this study with friends
Copy Link
Messenger